

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0751  
Inventors: Dean et al.  
Serial No.: Not Yet Assigned  
Filing Date: Herewith  
Examiner: Not Yet Assigned  
Group Art Unit: Not Yet Assigned  
Title: Antisense Modulation of Fas Mediated Signaling

"Express Mail" Label No. EV331019901US  
Date of Deposit July 14, 2003

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Mail Stop Sequence, P. O. Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata  
Typed Name: Jane Massey Licata, Reg. No. 32,257

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

( ) The fee of \$240.00 as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

( ) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)

are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/802,669 filed March 9, 2001, Serial No. 09/665,615, filed September 18, 2000, and application Serial No. 09/290,640, filed April 12, 1999, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

~~(XX)~~ All listed references are in the English language.

Respectfully submitted,

*Jane Massey Licata*

Jane Massey Licata  
Registration No. 32,257

Date: July 14, 2001

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. ISPH-0751	Serial No. Not yet assigned
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Dean et al.	
		Filing Date Herewith	Group Not yet assigned
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Du et al., "A Hammerhead Ribozyme That Cleaves Perforin and Fas-ligand RNA's in Vitro", Biochem. Biophys. Res. Commun., 1996, 226, 595-600	
	AB	Freiss et al., "Extinction of Insulin-Like Growth Factor-I Mitogenic Signaling by Antiestrogen-Stimulated Fas-Associated Protein Tyrosine Phosphatase-1 in Human Breast Cancer Cells", Mol. Endocrinol., 1998, 12, 568-579	
	AC	Herr et al., "Activation of CD95 (APO-1/FAS) signaling by ceramide mediates cancer therapy-induced apoptosis", EMBO J., 1997, 16, 6200-6208	
	AD	Lee et al., "The Fas System Is a Key Regulator of Germ Cell Apoptosis in the Testis*", Endocrinology, 1997, 138, 2081-2088	
	AE	O'Connell et al., "The Fas Counterattack: Fas-mediated T Cell Killing by Colon Cancer Cells Expressing Fas Ligand", J. Exp. Med., 1996, 184, 1075-1082	
	AF	Turley et al., "Vitamin E Succinate Induces Fas-mediated Apoptosis in Estrogen Receptor-Negative Human Breast Cancer Cells", Cancer Res., 1997, 57, 881-890	
	AG	Yu et al., "Vitamin E Succinate (VES) Induces Fas Sensitivity in Human Breast Cancer Cells: Role for M <sub>1</sub> 43,000 Fas in VES-triggered Apoptosis", Cancer Res., 1999, 59, 953-961	
EXAMINER		DATE CONSIDERED	